Associated with TTP with and estimated incidence of 1 case per 1600 to 5000 patients treated.
Prevents platelet aggregation by inhibiting ADP mediated platelet activation.
Principal use short-term use after intracoronary stent deployment.
In unstable angina results in a 50% reduction in vascular deaths and nonfatal MI at 6 months.
Requires CBC every two weeks for three months because of 1-2% neutropenia.
Has a delayed onset of action with maximum inhibition of ADP-induced platelet aggregation several days after administration.
Adverse effects include neutropenia in 2-3% of patients, agranulocytosis and TTP.
Ticlid associated aplastic anemia may be as high as one case in every 4000 to 8000 patients exposed.
The incidence of TTP peaks after about 3 to 4 weeks of treatment, neutropenia peaks at approximately 4 to 6 weeks, aplastic anemia peaks after about 4 to 8 weeks.
It is rare to have neutropenia, TTP, or aplastic anemia after more than 3 months of therapy.